Stocktoria
CASTLE BIOSCIENCES INC CSTL
Nasdaq · XNAS · stock · Services-Medical Laboratories · website · IPO 2019-07-25
CASTLE BIOSCIENCES INC statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating margin | -12.4% | 2.6% | -30.9% | -53.2% | -42.6% |
| Net margin | -7.0% | 5.5% | -26.1% | -49.0% | -33.3% |
| FCF margin | 8.2% | 11.0% | -8.8% | -34.5% | -23.9% |
| Return on assets | -4.2% | 3.4% | -12.7% | -15.0% | -6.8% |
| Return on equity | -5.1% | 4.0% | -14.7% | -16.8% | -7.6% |
| Debt / equity | 0.02× | 0.02× | 0.00× | — | — |
| Current ratio | 5.26 | 7.29 | 6.20 | 8.09 | 14.21 |
| Revenue growth | 3.7% | 51.1% | 60.4% | 45.7% | 50.2% |
Source: SEC EDGAR filings · CIK 0001447362 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.